Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease

Inflammatory Bowel Disease (G Lichtenstein, Section Editor)

Opinion statement

While anti-TNF agents have had a marked impact in the treatment of inflammatory bowel disease, a significant number of patients lose their response to these medications over time. Clinical trials have demonstrated that antibodies against anti-TNF medications may impact treatment response and increase the risk of infusion reaction. Scheduled dosing and concurrent use of immunomodulators may help to mitigate these risks via inhibiting the formation of these antibodies. The recent availability of assays to measure anti-TNF drug levels and antibodies against anti-TNFs offer the opportunity to assess patients who have lost response with infliximab and adalimumab, and potentially determine the most appropriate therapeutic strategy. There is growing evidence that such testing improves patient outcomes and is cost-effective, although heterogeneity in the assays used in clinical and observational trials has resulted in mixed results.

Keywords

Infliximab Adalimumab Certolizumab Azathioprine Immunomodulators Tumor necrosis factor-alpha (TNF-a) Anti-TNF drug levels Biologic Antibodies to infliximab (ATIs) Antibodies to adalimumab (ATAs) Crohn’s disease Ulcerative colitis 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Frank I. Scott declares that he has no conflict of interest.

Gary R. Lichtenstein has received consultancy payments from Abbott Corporation/Abbvie, Alaven, Bristol-Myers Squibb, Elan, Ferring, Hospira, Janssen Orthobiotech, Millenium Pharmaceuticals, Ono Pharmaceuticals, Pfizer Pharmaceuticals, Prometheus Laboratories, Inc., Salix Pharmaceuticals, Santarus, Shire Pharmaceuticals, Takeda, UCB, and Warner; honoraria from Ironwood and Luitpold / American Regent; and a research grant from Warner Chilcotte.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

  1. 1.
    Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95.PubMedCrossRefGoogle Scholar
  2. 2.
    Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006;130(4):1054–61.PubMedCrossRefGoogle Scholar
  3. 3.
    D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371(9613):660–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357(3):239–50.PubMedCrossRefGoogle Scholar
  7. 7.
    Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn’s disease: a critical systematic review. Inflamm Bowel Dis. 2009;15(8):1264–75.PubMedCrossRefGoogle Scholar
  8. 8.
    Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Ther Adv Gastroenterol. 2013;6(4):269–93.CrossRefGoogle Scholar
  9. 9.
    Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease. J Gastroenterol. Apr 11 2013.Google Scholar
  10. 10.
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33. quiz 591.PubMedCrossRefGoogle Scholar
  11. 11.
    Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357(3):228–38.PubMedCrossRefGoogle Scholar
  12. 12.
    Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab’)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 2011;60(1):41–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Ordas I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91(4):635–46.PubMedCrossRefGoogle Scholar
  14. 14.
    Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108(6):962–71.PubMedCrossRefGoogle Scholar
  15. 15.
    Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59(1):49–54.PubMedCrossRefGoogle Scholar
  16. 16.
    Khanna R, Sattin BD, Afif W, et al. Review article: a clinician’s guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(5):447–59.PubMedCrossRefGoogle Scholar
  17. 17.
    Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn’s disease. Am J Gastroenterol. 2008;103(4):944–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods. 2012;382(1–2):177–88.PubMedCrossRefGoogle Scholar
  19. 19.
    Infliximab Concentration and Anti-Infliximab Antibody. LabHorizons: a Newsletter for Clients. 11/2012 2012;13(11–12):3.Google Scholar
  20. 20.
    Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology. 2003;124(4):917–24.PubMedCrossRefGoogle Scholar
  22. 22.
    Vermeire S, Noman M, Van Assche G, Baert F, D’Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56(9):1226–31.PubMedCrossRefGoogle Scholar
  23. 23.
    Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc. 2004;2(7):542–53.CrossRefGoogle Scholar
  24. 24.
    Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc. 2006;4(10):1248–54.CrossRefGoogle Scholar
  25. 25.
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76.PubMedCrossRefGoogle Scholar
  26. 26.
    Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134(7):1861–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–65. e251-253.PubMedCrossRefGoogle Scholar
  28. 28.
    Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137(5):1628–40.PubMedCrossRefGoogle Scholar
  29. 29.
    Sandborn WJ, Abreu MT, D’Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn’s disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010;8(8):688–95. e682.PubMedCrossRefGoogle Scholar
  30. 30.
    Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493–507.PubMedCrossRefGoogle Scholar
  31. 31.
    Reinisch W, Feagan BG, Rutgeerts PJ, et al. Infliximab Concentration and Clinical Outcome in Patients With Ulcerative Colitis. Gastroenterology. 2012;142(5):S114 [Abstract].Google Scholar
  32. 32.
    Li J, Paulson SK, Chiu Y-L, Robinson A, Lomax KG, Pollac PF. Evaluation of potential correlations between serum adalimumab concentration and remission in patients with Crohn’s disease in classic I and II. Gastroenterology. 2010;138(5):S101 [Abstract].Google Scholar
  33. 33.
    Sandborn WJ, Schreiber S, Hanauer SB, Colombel JF, Bloomfield R, Lichtenstein GR. Reinduction with certolizumab pegol in patients with relapsed Crohn’s disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc. 2010;8(8):696–702. e691.CrossRefGoogle Scholar
  34. 34.
    Sandborn WJ, Hanauer SB, Pierre-Louis B, Lichtenstein GR. Certolizumab pegol plasma concentration and clinical remission in Crohn’s disease. Gastroenterology. 2012;142(5):S563 [Abstract Su2079].Google Scholar
  35. 35.
    Colombel JF, Feagan BG, Sandborn WJ, Van Assche G, Robinson AM. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(2):349–58.PubMedCrossRefGoogle Scholar
  36. 36.
    Afif W, Loftus E Jr, Faubion W, Kane S, Bruining D, Hanson K, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133–1139.Google Scholar
  37. 37.
    Pariente B, Pineton de Chambrun G, Krzysiek R, et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(7):1199–206.PubMedCrossRefGoogle Scholar
  38. 38.
    Vande Casteele N, Compernolle G, Ballet V, et al. Results on the optimisation phase of the prospective controlled trough level adapted infliximab treatment (TAXIT) trial. Gastroenterology. 2012;142(5):S211–2.Google Scholar
  39. 39.
    Vande Casteele N, Gils A, Ballet V, et al. Randomised controlled trial of drug level verus clinically based dosing of infliximan maintenance therapy in IBD: final results of the TAXIT study. U Eur Gastroenterol J. 2013;1:A1.CrossRefGoogle Scholar
  40. 40.
    Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. Jul 22 2013.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2014

Authors and Affiliations

  1. 1.Division of Gastroenterology, Department of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.IBD Program, Hospital of the University of Pennsylvania, Division of Gastroenterology, Department of MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations